📄 cardiovascular medicine
New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide
In a retrospective cohort study of over 420,000 patients with obesity, tirzepatide initiation was associated with a modestly lower risk of new-onset heart failure, all-cause mortality, and new-onset systolic heart failure compared to semaglutide over a one-year period.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.